The Pasteur Institute is looking for hundreds of patients to take part in clinical trials for a new treatment for Covid 19, amid reports of a drop in vaccination rates in France.
On Monday, the Lily-based research institute said it had signed up its first patient for the second phase of the trial, which was given the green light by the French National Agency for Safety of Medicine in June.
It hopes to recruit between 350 and 700 patients through medical clinics and laboratories labeled “National Research Priority”.
The institute said it would review the safety, tolerance and efficacy of “adaptive, outpatient, randomized, placebo-controlled, double-blind phase study”. Clofactol“In patients with early-stage symptomatic colic – to avoid hospitalization.
Clofactol is a small antiviral drug that treats respiratory, ear, nose and throat infections. Taken as an adjunct, it is already sold in France and other European countries for non-covid treatment.
Participants in Pasteur Clinical Trials must be over 50 years of age, unvaccinated, and present with at least one sign of Covid 19.
Look at the French West Indies
For now, only the northern Haute-de-France region bordering Belgium is being explored, but the Pasteur Institute said it would look for other areas – especially the French West Indies, where delta infections are rampant. have been.
In mainland France, more than 72% of people over the age of 12 have received at least one dose of the vaccine, and more than 60% have been fully vaccinated.
At the top, more than 120,000 vulnerable people have received a third booster shot since the campaign began on September 1.
The Pasteur Institute seems to be more likely to find candidates for its trials in the French Caribbean islands of Guadeloupe and Martinique, where there is more reluctance to vaccinate.
Official figures show that only 24% of martinians over the age of 12 have been fully vaccinated, bringing the number to 22% in Guadeloupe.
To fund its trial, the institute received a 5 million donation from luxury giant LVMH.